Source:http://linkedlifedata.com/resource/pubmed/id/10556676
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2000-1-13
|
| pubmed:abstractText |
In previous studies, 18-methoxycoronaridine, a novel iboga alkaloid congener, has been reported to decrease the self-administration of morphine, cocaine, ethanol and nicotine, and to attenuate naltrexone-precipitated signs of morphine withdrawal. In the present study, the nature of the interaction between 18-methoxycoronaridine and morphine was further investigated. Using in vivo microdialysis, 18-methoxycoronaridine pretreatment (40 mg/kg i.p., 19 h beforehand) was found to markedly inhibit morphine-induced (5 mg/kg, i.p.) dopamine release in the nucleus accumbens and striatum; 18-methoxycoronaridine also enhanced morphine-induced increases in extracellular levels of dopamine's metabolites. These effects, which were more prominent in the nucleus accumbens than in the striatum, suggest that 18-methoxycoronaridine selectively interferes with morphine-induced dopamine release, without altering morphine-induced stimulation of dopamine synthesis. In intravenous morphine self-administration experiments, the effects of acute 18-methoxycoronaridine treatment (40 mg/kg, p.o.) were assessed in rats responding for one of several different unit infusion dosages of morphine (0.01-0.16 mg/kg/infusion). 18-Methoxycoronaridine produced a downward shift in the entire morphine dose-response curve without any displacement to the left or right. These results suggest that 18-methoxycoronaridine reduced the reinforcing efficacy of morphine without altering its apparent potency. Together, the microdialysis and self-administration data suggest that 18-methoxycoronaridine profoundly alters mechanisms crucial to the development and maintenance of opioid addiction.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/18-methoxycoronaridine,
http://linkedlifedata.com/resource/pubmed/chemical/3,4-Dihydroxyphenylacetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Homovanillic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Ibogaine,
http://linkedlifedata.com/resource/pubmed/chemical/Morphine,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotics
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0014-2999
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
21
|
| pubmed:volume |
383
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
15-21
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:10556676-3,4-Dihydroxyphenylacetic Acid,
pubmed-meshheading:10556676-Animals,
pubmed-meshheading:10556676-Brain,
pubmed-meshheading:10556676-Dopamine,
pubmed-meshheading:10556676-Dose-Response Relationship, Drug,
pubmed-meshheading:10556676-Drug Antagonism,
pubmed-meshheading:10556676-Female,
pubmed-meshheading:10556676-Homovanillic Acid,
pubmed-meshheading:10556676-Ibogaine,
pubmed-meshheading:10556676-Microdialysis,
pubmed-meshheading:10556676-Morphine,
pubmed-meshheading:10556676-Narcotics,
pubmed-meshheading:10556676-Nucleus Accumbens,
pubmed-meshheading:10556676-Rats,
pubmed-meshheading:10556676-Rats, Long-Evans,
pubmed-meshheading:10556676-Rats, Sprague-Dawley,
pubmed-meshheading:10556676-Self Administration,
pubmed-meshheading:10556676-Time Factors,
pubmed-meshheading:10556676-Visual Cortex
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine.
|
| pubmed:affiliation |
Department of Pharmacology and Neuroscience, MC-136, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA. maison@ccgateway.amc.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|